Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7306MR)

This product GTTS-WQ7306MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7306MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5522MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ4543MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ8796MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ5276MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ12091MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ10467MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ9885MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ12379MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW